Success Story: NIW Victory After RFE! Chinese Postdoc Earns Approval Through Expert Support and Direct Premium Service

Client’s Testimonial:

“That’s great news! Thank you for your support throughout this RFE process!”

On July 17^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Case Filing: Postdoctoral Fellow

Country of Origin: China

State of Residence at the Time of Filing: New Jersey

Approval Notice Date: July 17^th, 2025

Processing Time: 3 months, 13 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a biomedical science researcher whose work is shaping the future of precision medicine and public health. At the time of filing, the client was engaged in advanced research at a major U.S. medical institution, where she continued to investigate complex diseases by integrating genetic, molecular, and population-level data.

Upon reviewing this case, North America Immigration Law Group (NAILG) determined that the client’s proposed endeavor, characterizing the genetic, molecular, and biological mechanisms underlying complex diseases, was of clear national significance. Her research targets high-impact medical conditions such as neuronal and psychiatric disorders, cancer, and other chronic diseases. By advancing knowledge of these conditions, her work supports early detection, precise diagnostics, and novel therapeutic development, all of which are essential to improving quality of life and reducing healthcare burdens across the United States. The client’s integrative approach, which combines bioinformatics, multi-omics analysis, artificial intelligence, and wet-lab validation, also contributes to public health policies and personalized medical strategies.

With a Ph.D. in pathology and interdisciplinary training in genetics, epidemiology, and bioinformatics, the client has cultivated a robust and impactful research portfolio. She has authored 2 peer-reviewed journal articles, 2 first-authored conference abstracts, and 2 preprints. These contributions have earned a total of 563 citations to date, including publications in top-tier journals. One of her articles has received over 500 citations and ranks among the top 0.1% most-cited papers in biology and biochemistry for its year. This level of recognition highlights the groundbreaking nature and broad influence of her work in the field.

In addition, her research has been directly cited and built upon in other high-impact studies addressing neuroinflammation, cellular signaling, and immunology, further reinforcing her central role in ongoing scientific progress. Through this impactful work, she has significantly advanced the biomedical community’s understanding of disease mechanisms and demonstrated her ability to lead transformative research at the intersection of biology, technology, and medicine.

Despite receiving a Request for Evidence, USCIS approved the EB-2 NIW petition within 3 months of filing under premium processing. This approval underscores the strength of the petition strategy crafted by NAILG and the compelling value of the client’s research to the United States. We are proud to have assisted this exceptional biomedical scientist in securing her NIW approval and look forward to her continued contributions to public health, medical research, and national scientific excellence.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.